Induction of centrosome and chromosome aberrations by imatinib in vitro
- 30 June 2005
- journal article
- Published by Springer Nature in Leukemia
- Vol. 19 (9) , 1573-1578
Abstract
Imatinib (STI571, Gleevec/Glivec) is a potent selective tyrosine kinase inhibitor and is used successfully in the treatment of chronic myeloid leukemia (CML). While karyotype alterations, in addition to the Philadelphia chromosome, are a common phenomenon of progressing CML, the observation of BCR-ABL-negative leukemic clones with distinct aberrant karyotypes under an imatinib regimen is not yet understood. Here we test the hypothesis that such tumor clones may be induced de novo from normal cells by imatinib. In vitro experiments with varying drug concentrations (5–20 M) were performed on normal human dermal fibroblasts (NHDF), Chinese hamster embryonal and Indian muntjak fibroblasts. After 3 weeks of treatment, analysis of cell cultures by centrosome immunostaining and conventional cytogenetics revealed that imatinib induced centrosome and chromosome aberrations in all cultures in a significant dose-dependent and species-independent manner. Moreover, the results of NHDF long-term culture experiments demonstrated that aberrant phenotypes, emerging under imatinib treatment for 12 weeks, were not reversible after prolonged propagation omitting the drug. These observations suggest a causative role of imatinib in the origin of centrosome and karyotype aberrations (genetic instability) and thus may explain the emergence of clonal chromosomal abnormalities in BCR-ABL-negative progenitor cells under imatinib therapy.Keywords
This publication has 42 references indexed in Scilit:
- Centrosome aberrations – hen or egg in cancer initiation and progression?Leukemia, 2005
- Macrophage colony-stimulating factor receptor c-fms is a novel target of imatinibBlood, 2005
- The development of imatinib as a therapeutic agent for chronic myeloid leukemiaBlood, 2005
- Response and resistance in 300 patients with BCR‐ABL–positive leukemias treated with imatinib in a single centerCancer, 2005
- The biology of CML blast crisisBlood, 2004
- Overexpression of mammalian Rad51 does not stimulate tumorigenesis while a dominant-negative Rad51 affects centrosome fragmentation, ploidy and stimulates tumorigenesis, in p53-defective CHO cellsOncogene, 2003
- Demonstration of Philadelphia chromosome negative abnormal clones in patients with chronic myelogenous leukemia during major cytogenetic responses induced by imatinib mesylateLeukemia, 2003
- Chronic Myeloid LeukemiaNew England Journal of Medicine, 1999
- Regulation of Rad51 Function by c-Abl in Response to DNA DamageJournal of Biological Chemistry, 1998
- Report of the committee on chromosome markersCytogenetic and Genome Research, 1976